HC Wainwright reiterated their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL – Free Report) in a report released on Thursday, Marketbeat reports. The brokerage currently has a $1.00 target price on the stock, down from their prior target price of $6.00.
Lyell Immunopharma Stock Up 5.1 %
Shares of NASDAQ LYEL opened at $1.45 on Thursday. The firm has a 50-day simple moving average of $2.39 and a 200-day simple moving average of $2.24. The stock has a market capitalization of $369.66 million, a price-to-earnings ratio of -1.61 and a beta of -0.40. Lyell Immunopharma has a 52 week low of $1.18 and a 52 week high of $3.41.
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last released its earnings results on Monday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. As a group, equities research analysts expect that Lyell Immunopharma will post -0.85 EPS for the current year.
Hedge Funds Weigh In On Lyell Immunopharma
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Read More
- Five stocks we like better than Lyell Immunopharma
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- MarketBeat Week in Review – 6/24 – 6/28
- The How and Why of Investing in Gold Stocks
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.